

# Project Roc Opportunity to receive investment and licensing

Corporate finance

PRECISE. PROVEN. PERFORMANCE.

## Leading Chinese IVD manufacturer seeking biotech investments

### Introduction

- A leading Chinese in vitro diagnostic (“IVD”) manufacturer (the “Company”) is seeking global investments and/or licencing opportunities in biotech.
- Funding available up to USD50 million with maximum USD5 million per identified target company / project (including both investment and licensing).
- Hands on support from the early stage of advanced and innovative IVD technology to industrialisation, entering one of the fastest growing and biggest markets – China (IVD market year on year increase c.15-20% with a total size of USD6.5 billion).
- Investment focus on non-Chinese companies, which have at least developed a prototype in areas including molecular diagnostics, immunoassay, biochemistry and point of care.

### Investment company overview

- The Company is a Chinese pioneering IVD technology transfer platform; it is also one of the largest IVD raw materials supplier and reagent solution provider in China.
- It brings the world’s most innovative IVD technologies into the Chinese market, and helps to commercialise and distribute in the local market.
- Over the past 15 years of R&D accomplishments, the Company invested in over 700 antigen and antibody products, which are currently sold to over 600 customers in more than 30 countries worldwide.
- Over half of the Company’s 300 employees are focusing on R&D and it owns numerous invention patents and application patents in China.
- The Company has deep understanding of the Chinese and Asian markets and provides strong resources and support in the areas of finance, manufacturing, R&D as well as China Food and Drug Administration (“CFDA”) registrations.

### Investment focus

- Platforms and reagents including:
  - Molecular Diagnostics
  - Immunoassay
  - Biochemistry
  - Point of Care
- Also new technologies of life sciences in the areas of:
  - Next generation sequencing
  - Liquid Biopsy
  - CTC
  - Digital PCR
  - IVD innovative platform and technology
  - Cell therapy
  - Antibody drug discovery



**The content of this promotion has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000.**

**Moore Stephens LLP is not acting for recipients of this promotion and will not be responsible to recipients for providing protections afforded to clients of the firm. Moore Stephens LLP will not provide investment advice to recipients of this promotion in relation to this transaction. Recipients may wish to seek their own professional advice on the transaction.**



**Rich experience  
in the  
bio-industry**



**Deep  
understanding  
of the local  
market**



**Strong capital  
and available  
funding**



**Technical  
excellence with  
skilful  
professionals**



**Matured and  
stable  
customer  
network**

### Other investment criteria

- **Stage of development of the target business:** after the prototype has been developed.
- **Size of the target business:** mature companies are preferred but if the technology is innovative and ground-breaking, early stage is also acceptable. The target business should have at least 10 employees.
- **Target business locations:** targets outside of China and which currently have no presence in China; the Company is looking to obtain licensing and distribution exclusivity in China (usually for at least 10 years).

### Further information

For further information on this opportunity please contact:

#### Marty Lau – Partner

E [marty.lau@moorestephens.com](mailto:marty.lau@moorestephens.com)  
D +44 (0) 20 7334 9191  
M +44 (0) 7899 070 609

#### Victoria Kiess – Senior Manager

E [victoria.kiess@moorestephens.com](mailto:victoria.kiess@moorestephens.com)  
D +44 (0) 7947 951 006  
M +44 (0) 7947 951 006

#### Jinjing Xie – Senior Manager

E [jinjing.xie@moorestephens.com](mailto:jinjing.xie@moorestephens.com)  
D +44 (0) 20 7651 1849  
M +44 (0) 7588 116 868

This document has been prepared for private circulation only and should not be transmitted in any form without Moore Stephens LLP's prior consent. Should such consent be given any person transmitting this document is responsible for their own compliance with the Financial Services and Markets Act 2000. By accepting this document, the recipient agrees to keep this document confidential and not to reproduce it in whole or in part or distribute it without the consent of the Company. At the request of the Company, the recipient must promptly return the document and all reproductions in whole or in part to the Company.

The information and opinions contained in this document are for background purposes only and do not purport to be full or complete representation, warranty or undertaking, express or implied, is made and no responsibility is accepted by the Company, Moore Stephens LLP, or any other party as to the accuracy or completeness in any respect of any information contained or statement made herein. All information in this document is subject to change without notice.

Moore Stephens LLP is a limited liability partnership, registered in England and Wales with registered number OC313071. A list of members' names is available for inspection at 150 Aldersgate Street, London EC1A 4AB, the firm's principal place of business and registered office. Authorised and regulated by the Financial Conduct Authority for investment business.

The distribution of this document in certain jurisdictions may be restricted by law and therefore persons into whose possession this document comes should inform themselves about and observe any such restrictions. This document is not for distribution outside the United Kingdom save to the extent that it would be lawful to do so. DPS38279